百时美施贵宝Bristol Myers Squibb Co. (BMY) 2006年年度报告「NYSE」.pdf

1、NOPQTheir will.Our medicines.Together we can prevail.2006 Annual Report Our companys mission is to extend and enhance human lifeby providing the highest-quality pharmaceutical and relatedhealth care products.We pledgeto our patients and customers,to our employees and partners,to our shareholders and

2、 neighbors,and to the world we serveto act on our belief that thepriceless ingredient of every product is the honor and integrity of its maker.MissionBristol-Myers SquibbsON THE COVER:At Bristol-Myers Squibb,we develop medicines andrelated health care products to help people live full and active liv

3、es.A few of our patients and customersare pictured on the cover.These and other patients are profiled in our Special Report,beginning on page 7.Sales and earnings were adversely affectedby several developments in the year.First,asexpected,we lost exclusivity on Pravachol,ourcholesterol-lowering medi

4、cine,in the U.S.andin several European countries.For many years,Pravachol was one of our leading products.More recently,we experienced the negativeimpact of generic competition with our top-selling product Plavix(clopidogrel bisulfate),anantiplatelet medicine that Bristol-Myers Squibband sanofi-aven

5、tis(Sanofi)are codevelopingand co-commercializing around the world.In August 2006,the Canadian pharmaceuticalcompany Apotex launched its generic versionof Plavix in the U.S.,flooding the market forseveral weeks until sales were halted by acourt order.This action by Apotex reducedour Plavix sales in

6、the range of$1.2 billion to$1.4 billion in 2006,and was reflected in anoverall 15 percent decline in Plavix sales forthe year.We expect the generic supply in the market will have a residual impact on2007 Plavix sales.FINANCIAL PERFORMANCEIn 2006,the companys net earnings fromcontinuing operations on